Navigation Links
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
Date:5/9/2008

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a centrally acting oral analgesic, provided significant relief for patients with joint-disease pain, compared to those treated with placebo, and with fewer gastrointestinal side effects than those treated with an older, prescription pain reliever, researchers announced today.

Results from a Phase 3 clinical study of tapentadol immediate release (IR) tablets showed that patients treated with a 50 mg or 75 mg dose of tapentadol experienced significant relief in end-stage joint disease pain compared to placebo (P<0.001) when assessed over five days of treatment. In addition, patients treated with tapentadol experienced significantly better digestive tract tolerability compared to patients treated with 10 mg of oxycodone IR. Digestive tract tolerability is one of the leading causes of treatment discontinuation for patients who take prescription pain medications.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) presented these new data in a poster session at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

Tapentadol has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for chronic pain.

Mu-opioid agonists are drugs that bind to and activate mu-opioid receptors in the central nervous system. These drugs modify sensory and affective (mood) aspects of pain, inhibit the transmission of pain at the spinal cord and affect activity at parts of the brain that control how pain is perceived. Nor
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:8/29/2014)... The new review that can be read on DailyGossip.org indicates ... will permanently eliminate the symptoms of this disease. , ... cure in as fast as 30 to 60 days. However, ... week. , The Tinnitus Miracle review indicates that this ... loss, pain in the ear and dizziness. Read the full ...
(Date:8/29/2014)... Cosmetic Town is a cosmetic ... plastic surgeons with prospective patients. The site showcases ... techniques in plastic and reconstructive surgery. Articles are ... reliable information for general readers, who are looking ... Town began featuring renowned cosmetic specialists from Los ...
(Date:8/29/2014)... The Nasal Polyps Treatment Miracle ... new program is actually based on some powerful ... by a former nasal polyps sufferer, who in ... problem. Manuel Richards suffered from nasal polyps for ... , Learn more about Manuel Richards' new book ...
(Date:8/29/2014)... The Department of Health and Human ... code CMS–0052–P) today allowing healthcare providers to attest for ... EHR Technology (CEHRT) or a combination of the 2011 ... not been able to fully implement 2014 Edition CEHRT ... continue to use 2011 Edition CEHRT, or a combination ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2
... of a ban on Coke and Pepsi by the Kerala Government, ... putting forth a proposal to stop the sale// and production of ... ,Top brass in the companies are very unhappy over these ... private company which is not in sync with the reports ...
... Minister Tony Abbott yesterday accused the commonwealth of bankrolling ... public money was spent.// ,He attacked ... should be able to fund public hospitals using the ... ,State health ministers, outraged at Mr Abbott's position accused ...
... too much take-away food and pile on weight will soon ... ,The National Heart Foundation's tick is a label that ... and will soon make its appearance at restaurants, take-away outlets ... by analyst BIS Shrapnel who showed that 70 percent of ...
... for one to undergo an operation.// ,A team ... analysed the outcomes of over 90,000 operations carried out at ... time to have an operation, as they had found that ... published their study in the journal Quality and Safety in ...
... eating raw shellfish have made the U.S. Food and ... raw shellfish. Reports coming// in show that oysters and ... sick across the country. ,Till date there have been ... gastroenteritis after eating raw shellfish. The illness is caused ...
... condition that affects children as well as adults. A ... alleviate// symptoms and bring down the inflammation associated with ... 10 issue of the New England Journal of Medicine. ... the National Institute of Arthritis and Musculoskeletal and Skin ...
Cached Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Heart Tick for Fast Foods in Australia 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
... Skin Staple Remover is a plastic ... is packaged 12 units per box ... staples. The device works by slipping ... under the staple to be removed. ...
... place single staples to close surgical ... stainless steel; the staplers are not ... skin staplers to meet your needs., ... for routine skin closure in a ...
... is a full-feature skin stapler with a ... has improved visibility over existing fixed-head skin ... for easier staple placement., ,This Skin ... instrument designed to deliver rectangular, stainless steel ...
... Linear Staplers are available with either a ... instrument (non-reloadable). Each instrument contains 19 staples ... ,Benefits include: , Small profile stapling head ... , Articulating head rotates up to 80deg; ...
Medicine Products: